BRPI0511253A - composição farmacêutica - Google Patents

composição farmacêutica

Info

Publication number
BRPI0511253A
BRPI0511253A BRPI0511253-2A BRPI0511253A BRPI0511253A BR PI0511253 A BRPI0511253 A BR PI0511253A BR PI0511253 A BRPI0511253 A BR PI0511253A BR PI0511253 A BRPI0511253 A BR PI0511253A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
diluent
pharmaceutically acceptable
acceptable salt
substantially insoluble
Prior art date
Application number
BRPI0511253-2A
Other languages
English (en)
Inventor
Paul William Stott
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0511253A publication Critical patent/BRPI0511253A/pt
Publication of BRPI0511253B1 publication Critical patent/BRPI0511253B1/pt
Publication of BRPI0511253B8 publication Critical patent/BRPI0511253B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

COMPOSIçãO FARMACêUTICA. Uma composição farmacêutica contendo ZD6474 ou um seu sal farmaceuticamente aceitável, um diluente quebradiço e um segundo diluente que é praticamente insolúvel e tem propriedades de compressão dúctil.
BRPI0511253A 2004-05-21 2005-05-18 composição farmacêutica BRPI0511253B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0411378.3 2004-05-21
GBGB0411378.3A GB0411378D0 (en) 2004-05-21 2004-05-21 Pharmaceutical compositions
PCT/GB2005/001931 WO2005112934A1 (en) 2004-05-21 2005-05-18 Pharmaceutical compositions comprising zd6474

Publications (3)

Publication Number Publication Date
BRPI0511253A true BRPI0511253A (pt) 2007-11-27
BRPI0511253B1 BRPI0511253B1 (pt) 2020-03-31
BRPI0511253B8 BRPI0511253B8 (pt) 2021-05-25

Family

ID=32607743

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511253A BRPI0511253B8 (pt) 2004-05-21 2005-05-18 composição farmacêutica

Country Status (33)

Country Link
US (1) US8067427B2 (pt)
EP (1) EP1753431B1 (pt)
JP (1) JP4740947B2 (pt)
KR (1) KR101192935B1 (pt)
CN (1) CN101031303B (pt)
AR (2) AR049059A1 (pt)
AT (1) ATE439841T1 (pt)
AU (1) AU2005244650B2 (pt)
BR (1) BRPI0511253B8 (pt)
CA (1) CA2565513C (pt)
CY (1) CY1109500T1 (pt)
DE (1) DE602005016105D1 (pt)
DK (1) DK1753431T3 (pt)
ES (1) ES2330025T3 (pt)
GB (1) GB0411378D0 (pt)
HR (1) HRP20090547T1 (pt)
IL (1) IL178928A (pt)
ME (2) ME01505B (pt)
MX (1) MXPA06013501A (pt)
MY (1) MY138868A (pt)
NO (1) NO338324B1 (pt)
NZ (1) NZ550931A (pt)
PL (1) PL1753431T3 (pt)
PT (1) PT1753431E (pt)
RS (1) RS51112B (pt)
RU (1) RU2383343C2 (pt)
SA (1) SA05260133B1 (pt)
SI (1) SI1753431T1 (pt)
TW (1) TWI355269B (pt)
UA (1) UA81732C2 (pt)
UY (1) UY28901A1 (pt)
WO (1) WO2005112934A1 (pt)
ZA (1) ZA200609110B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2278511B1 (es) * 2005-07-28 2008-06-16 Laboratorios Almirall S.A. Comprimidos con perfil de disolucion mejorado.
ES2813877T3 (es) 2013-08-28 2021-03-25 Crown Bioscience Inc Taicang Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos
WO2025256594A1 (en) * 2024-06-12 2025-12-18 Centre for Eye and Vision Research Limited Methods and compositions for treating refractive errors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
KR100881105B1 (ko) * 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
KR100419555B1 (ko) * 2000-05-29 2004-02-19 주식회사유한양행 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
JP4542783B2 (ja) * 2002-03-05 2010-09-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有複素環化合物及び血管新生抑制剤とを組み合わせてなる抗腫瘍剤

Also Published As

Publication number Publication date
TW200612953A (en) 2006-05-01
CA2565513A1 (en) 2005-12-01
US8067427B2 (en) 2011-11-29
US20070244323A1 (en) 2007-10-18
CN101031303B (zh) 2011-08-31
HK1099220A1 (en) 2007-08-10
DK1753431T3 (da) 2009-11-16
BRPI0511253B1 (pt) 2020-03-31
KR20070034499A (ko) 2007-03-28
AR049059A1 (es) 2006-06-21
PT1753431E (pt) 2009-10-14
RU2006145357A (ru) 2008-06-27
NZ550931A (en) 2009-05-31
SI1753431T1 (sl) 2009-12-31
EP1753431A1 (en) 2007-02-21
TWI355269B (en) 2012-01-01
AU2005244650A1 (en) 2005-12-01
MY138868A (en) 2009-08-28
CY1109500T1 (el) 2014-08-13
BRPI0511253B8 (pt) 2021-05-25
AU2005244650B2 (en) 2008-04-10
RU2383343C2 (ru) 2010-03-10
JP4740947B2 (ja) 2011-08-03
KR101192935B1 (ko) 2012-10-18
ME02778B (me) 2010-10-31
PL1753431T3 (pl) 2009-12-31
GB0411378D0 (en) 2004-06-23
ME01505B (me) 2014-04-20
WO2005112934A1 (en) 2005-12-01
HRP20090547T1 (hr) 2009-11-30
UA81732C2 (ru) 2008-01-25
JP2007538060A (ja) 2007-12-27
EP1753431B1 (en) 2009-08-19
NO338324B1 (no) 2016-08-08
CA2565513C (en) 2010-10-19
ATE439841T1 (de) 2009-09-15
MXPA06013501A (es) 2007-06-12
ZA200609110B (en) 2008-06-25
ES2330025T3 (es) 2009-12-03
UY28901A1 (es) 2005-12-30
RS51112B (sr) 2010-10-31
NO20065735L (no) 2006-12-19
IL178928A0 (en) 2007-03-08
IL178928A (en) 2012-04-30
SA05260133B1 (ar) 2008-12-23
AR110045A2 (es) 2019-02-20
CN101031303A (zh) 2007-09-05
DE602005016105D1 (de) 2009-10-01

Similar Documents

Publication Publication Date Title
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
CL2017001847A1 (es) Una formulación sólida de dosificación farmacéutica
CL2007003604A1 (es) Composicion farmaceutica para administrar oral que comprende el compuesto 17-aminogeldanamicina amorfo; y su uso en el tratamiento del cancer.
TW200733971A (en) CGRP peptide antagonists and conjugates
BRPI0714399B8 (pt) composição farmacêutica líquida oral
MX2009004965A (es) Formas de dosificacion y co-administracion de un agonista de opioides y un antagonista de opioides.
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
ATE449081T1 (de) Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
MX2010007083A (es) Combinacion anti-retroviral.
TNSN07359A1 (en) Association between ferroquine and an artemisinine derivative for treating malaria
MA31706B1 (fr) Formulations galéniques de composés organiques
MX2008001549A (es) 3,11b-cis-dihidrotetrabenazina para el tratamiento de esquizofrenia y otras psicosis.
BRPI0415053B8 (pt) inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
UA91848C2 (ru) Применение соединений диосметина в лечении и предотвращении тромботическим патологиям
BRPI0511253A (pt) composição farmacêutica
WO2008020314A3 (en) Statin stabilizing dosage formulations
TW200730190A (en) New combination to treat liver fibrosis
DE60301261D1 (de) Pharmazeutische zusammensetzungen enthaltend 17alpha-furanylester von 17beta-carbothioat androstanderivaten und einen muskarinrezeptorantagonist
AR063656A1 (es) Composiciones que comprenden una combinacion de antagonistas de ccr5 y cxcr4
WO2004071385A3 (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention
MX2007013468A (es) Composiciones que contienen tanaproget micronizado.
CL2008002555A1 (es) Composicion farmaceutica que comprende un compuesto de levosimendan y un segundo ingrediente activo un antagonista del receptor de angiotensiva ii; un kit farmaceutico que comprende dicha composicion; y su uso para la prevencion o la inhibicion de apoplejia.
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
EP1680098A4 (en) DELAYED RELEASE OF POSITIVELY-LOADED PHARMACOLOGICALLY EFFECTIVE MOLECULES FROM A POLYMER-CONTAINING MATRIX WITH POLARIZED OXYGENATOMES

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: GENZYME CORPORATION (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 31/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/05/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.